BioMarin Pharmaceutical (BMRN) Tops Q2 EPS By 10c; Raises Low-End of FY Revenue Guidance
Tweet Send to a Friend
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) reports Q2 EPS of $0.09, 10 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
